


This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended): A compound ~~Compounds of the~~ formula I



in which

- R^1, R^2 are each, independently of one another, H, =O, Hal, A, ethynyl, OR^3 , $\text{N}(\text{R}^3)_2$, NO_2 , CN, N_3 , COOR^3 , $\text{CON}(\text{R}^3)_2$, $-\text{C}(\text{R}^4)_2]_n\text{-Ar}$, $-\text{C}(\text{R}^4)_2]_n\text{-Het}$, $-\text{C}(\text{R}^4)_2]_n\text{-cycloalkyl}$, $-\text{OCOR}^3$, $-\text{OCON}(\text{R}^3)_2$, NR^3COA or $\text{NR}^3\text{SO}_2\text{A}$,
- R^1 and R^2 together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms,
- R^3 is H, A, $\text{H-C}\equiv\text{C-CH}_2\text{-}$, $\text{CH}_3\text{-C}\equiv\text{C-CH}_2\text{-}$, $-\text{CH}_2\text{-CH}(\text{OH})\text{-CH}_2\text{OH}$, $-\text{CH}_2\text{-CH}(\text{OH})\text{-CH}_2\text{NH}_2$, $-\text{CH}_2\text{-CH}(\text{OH})\text{-CH}_2\text{Het}'$, $-\text{C}(\text{R}^4)_2]_n\text{-Ar}'$, $-\text{C}(\text{R}^4)_2]_n\text{-Het}'$, $-\text{C}(\text{R}^4)_2]_n\text{-cycloalkyl}$, $-\text{C}(\text{R}^4)_2]_n\text{-COOA}$ or $-\text{C}(\text{R}^4)_2]_n\text{N}(\text{R}^4)_2$,
- R^4 is H or A,
- W is N, CR^3 or an sp^2 -hybridised carbon atom,
- E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atom which optionally contains ~~may contain~~ a double bond,
- D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR^3 , $\text{N}(\text{R}^3)_2$, NO_2 , CN, COOR^3 or $\text{CON}(\text{R}^3)_2$,
- G is $-\text{C}(\text{R}^4)_2]_n\text{-}$, $-\text{C}(\text{R}^4)_2]_n\text{NR}^3\text{-}$, $-\text{C}(\text{R}^4)_2]_n\text{O-}$, $-\text{C}(\text{R}^4)_2]_n\text{S-}$ or $-\text{C}(\text{R}^4)=\text{C}(\text{R}^4)]_n\text{-}$,
- X is $-\text{C}(\text{R}^4)_2]_n\text{CONR}^3[\text{C}(\text{R}^4)_2]_n\text{-}$, $-\text{C}(\text{R}^4)_2]_n\text{NR}^3\text{CO}[\text{C}(\text{R}^4)_2]_n\text{-}$, $-\text{C}(\text{R}^4)_2]_n\text{NR}^3[\text{C}(\text{R}^4)_2]_n\text{-}$, $-\text{C}(\text{R}^4)_2]_n\text{O}[\text{C}(\text{R}^4)_2]_n\text{-}$,



- Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T is a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by =O, =S, =NR³, =N-CN, =N-NO₂, =NOR³, =NCOR³, =NCOOR³ or =NOCOR³ and which is optionally further ~~may~~ ~~furthermore be~~ monosubstituted, disubstituted or trisubstituted by R³, Hal, A, -[C(R⁴)₂]_n-Ar, -[C(R⁴)₂]_n-Het, -[C(R⁴)₂]_n-cycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR³ and/or S(O)_nA,
- A is unbranched or branched alkyl having 1-10 carbon atoms in which one or two CH₂ groups are each optionally ~~may be~~ replaced by O or S atoms and/or by -CH=CH- groups and/or in addition 1-7 H atoms are each optionally ~~may be~~ replaced by F,
- Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R⁴)₂]_n-COOR³ or -O[C(R⁴)₂]_o-COOR³,
- Ar' is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂N(R⁴)₂, S(O)_nA, -[C(R⁴)₂]_n-COOR⁴ or -O[C(R⁴)₂]_o-COOR⁴,
- Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is ~~may be~~ unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, -[C(R⁴)₂]_n-Ar, -[C(R⁴)₂]_n-Het', -[C(R⁴)₂]_n-cycloalkyl, OR³, N(R³)₂, NR³CON(R³)₂, NO₂, CN, -[C(R⁴)₂]_n-COOR³, -[C(R⁴)₂]_n-CON(R³)₂, NR³COA, NR³SO₂A, COR³, SO₂NR³, S(O)_mA and/or carbonyl oxygen,
- Het' is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is ~~may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, =N(R⁴)₂, Hal, A,

OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂,
NR⁴SO₂A, COR⁴, SO₂NR⁴ and/or S(O)_nA,

Hal is F, Cl, Br or I,

n is 0, 1 or 2, and

o is 1, 2 or 3; [[,]]

or a and pharmaceutically usable derivative, solvate, salt, or stereoisomer derivatives,
~~solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, ~~in~~
~~which wherein~~ D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having
from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted
by Hal, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, ~~in~~
~~which wherein~~ D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of which in each case is~~
monosubstituted or disubstituted by Hal, ~~and pharmaceutically usable derivatives, solvates,~~
~~salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

4. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in~~
~~which wherein~~ R¹ [[,]] and R² are each, independently of one another, H, =O, COOR³, OH,
OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA,
NHSO₂A, OCH₂COOA or OCH₂COOH, ~~and pharmaceutically usable derivatives, solvates,~~
~~salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

5. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in~~
~~which wherein~~ G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-, ~~and~~
~~pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including~~
~~mixtures thereof in all ratios.~~

6. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ X is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n-$, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

7. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ X is $-CONH-$ or $-CON(CH_2COOA)-$, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ Y is cycloalkylene, Het-diyl or Ar-diyl, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

9. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, $COOCH_3$, $COOH$, phenoxy or aminocarbonyl, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

10. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by $=O$, $=S$ or $=NH_2$ and which is optionally further ~~may be~~ monosubstituted or disubstituted by Hal, A and/or OA, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

11. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by $=O$ or $=NH_2$ and where the radicals which is optionally further ~~may also be~~ monosubstituted or disubstituted by Hal, A and/or OA, ~~and pharmaceutically usable~~

~~derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

12. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂, CN, COOA, COOH or phenoxy, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

13. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by Hal,

R¹ and [[,]] R² are each, independently of one another, H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH, or R¹ and R² together are ~~alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H, A, phenyl, benzyl or [C(R⁴)₂]_nCOOA,

R⁴ is H or A,

W is N, CR³ or an sp²-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains ~~may contain~~ a double bond,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is -[C(R⁴)₂]_nCONR³[C(R⁴)₂]_n-,

Y is cycloalkylene, Het-diyl or Ar-diyl,

Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂, CN, COOA, COOH₂ or phenoxy,

T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH₂ and which is optionally further ~~may be~~ monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

14. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of which~~ in each case is monosubstituted or disubstituted by Hal,

R¹ and [[,]] R² are each, independently of one another, H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH, or R¹ and R² together are ~~alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H, A or CH₂COOA,

R⁴ is H or A,

W is N, CR³ or an sp²-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains ~~may contain~~ a double bond,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is -CONH- or -CON(CH₂COOA)-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH₃, COOH, phenoxy or aminocarbonyl,

T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, ~~each of which~~ in each case is monosubstituted or disubstituted by =O or =NH, and which is optionally further ~~where the radicals may also be~~ monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

15. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, ~~each of which~~ in each case is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, ~~each of which~~ in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H

atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

16. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, ~~each of which~~ in each case is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~_____ and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

17. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ X is $-\text{C}(\text{R}^4)_2\text{CONR}^3\text{C}(\text{R}^4)_2\text{-}$ or $-\text{C}(\text{R}^4)_2\text{CO}\text{C}(\text{R}^4)_2\text{-}$, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

18. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~ X is CONH or COCH_2 , ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

19. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which wherein~~

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R^1 is H, =O, COOR^3 , OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3 , ethynyl, vinyl, allyloxy, $-\text{OCOR}^3$, NHCOA or NHSO_2A ,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(\text{CH}_2)_n$ or $(\text{CH}_2)_n\text{NH-}$,

X is CONH or COCH_2 ,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

20. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in~~ which wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA, NHSO₂A, H-C≡C-CH₂-, CH₃-C≡C-CH₂-O-, -O-CH₂-CH(OH)-CH₂OH, -O-CH₂-CH(OH)-CH₂NH₂ or -O-CH₂-CH(OH)-CH₂Het',

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH or COCH₂,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which is ~~may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH₂, NO₂, CN, COOA or CONH₂,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

21. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is ethynyl, vinyl, allyloxy, CH₃-C≡C-CH₂-O-, -O-CH₂-CH(OH)-CH₂OH, -O-CH₂-CH(OH)-CH₂NH₂ or -O-CH₂-CH(OH)-CH₂Het',

R² is H or OH,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH, CO, COO or COCH₂,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-

[2.2.2]octan-2-yl, ~~each of which~~ in each case is monosubstituted or disubstituted by carbonyl oxygen or OA,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which ~~is may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH₂, NO₂, CN, COOA or CONH₂,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

22. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is CONH, COCH₂ or -CON(CH₂COOA)-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene, which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH₃, COOH, phenoxy or aminocarbonyl,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

23. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein said compound is selected from: the group consisting of

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-

dihydropyrrole-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[3-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[4-chlorophenyl]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1 λ ⁶-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1 λ ⁶-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-thiazolidine-3,4-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[3-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(2-oxopyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N- {[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl acetate,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1-BOC-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-oxazinane-3,4-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

6-N-[4-chlorophenyl]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-4-oxopyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(*S*)-pyrrolidine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2*R*,4*R*)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-3-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-6-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4,4-difluoro-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[4-(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*S*)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2*R*,4*R*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2*R*,4*S*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2*S*,4*R*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)phenoxy]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]]-(2*R*,4*R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*R*,4*R*)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]]-(*R*)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]]-(*R*)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(*R*)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(*R*)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*S*,3*S*)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2*S*,4*S*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-methoxycarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{N-methoxycarbonylmethyl-N'-[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)cyclohexan-1-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 442~~;

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 456~~;

1-N-[(4-chlorophenyl)]-2-N-[4-{2-[(E)-cyanimino]imidazolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 468~~;

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-imino-5-methylthiazol-3-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 473~~;

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 502~~;

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(2E,4E)-5-phenylpenta-2,4-dienyloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-2-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)-2-phenoxyphenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. (Currently Amended): A pyrrolidinecarboxylic ~~Pyrrolidinecarboxylic~~ acid compound ~~derivatives~~ selected from: ~~the group consisting of~~

1-N-[(4-chlorophenyl)]-2-N-[(1'-methyl-[1,4']bipiperidiny-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridiny-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridiny-4-yl)]-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-4-yl)piperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(2-methoxyphenyl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-hydroxy-4-(4-methoxyphenyl)piperidine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-2-yl)piperazine-1-carbonylpyrrolidine-1-carboxamide,
 N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-ethylpiperazin-1-yl)piperidine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,
 N-(4-chlorophenyl)-(2R,4R)-2-[4-(4,6-dimethylpyrimidin-2-yl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,
 N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(1-methylpiperidin-4-yl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,
 1-N-[(4-chlorophenyl)]-2-N-{[2-(2-dimethylaminoethoxy)-4-morpholin-4-ylphenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-[(4-chlorophenyl)]-2-N-[(2-ethoxy-4-morpholin-4-ylphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-[(4-chlorophenyl)]-2-N-[(4-morpholin-4-yl-2-propoxyphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25. (Currently Amended): A cyclopentanecarboxylic acid derivatives compound selected from: ~~the group consisting of~~ Cyclopentanecarboxylic acid


N-[4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,
 N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)ureido]cyclopentanecarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended): A process ~~Process~~ for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, ~~characterised in that~~ said process comprising

a) for the preparation of compounds of the formula I in which W is N and G is NH,

a compound of ~~the~~ formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of ~~the~~ formula III




in which

D is as defined in Claim 1,

or


b) for the preparation of compounds of ~~the~~ formula I in which X is -
 $[\text{C}(\text{R}^4)_2]_n \text{CONR}^3 [\text{C}(\text{R}^4)_2]_n$ -,

a compound of ~~the~~ formula IV



in which R^3 , n, Y and T are as defined in Claim 1,

is reacted with a compound of ~~the~~ formula V




in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and R^1 , R^2 , R^4 , D, E, G, W and n are as defined in Claim 1,

or

c) for the preparation of compounds of ~~the~~ formula I in which W is N,

a compound of ~~the~~ formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of ~~the~~ formula VI



in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. Cancelled

28. Cancelled.

29. (Currently Amended): A medicament composition ~~Medicament~~ comprising at least one compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,~~ and, ~~if desired,~~ one or more excipients and/or adjuvants.

30. (Currently Amended): A medicament composition ~~Medicament~~ comprising at least one compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and at least one further medicament active ingredient.

31. (Currently Amended): A method ~~Use of compounds according to claim 1 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament~~ for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim 1 .

32. (Currently Amended): A kit comprising ~~Set (kit) consisting of~~ separate packs of:


(a) an effective amount of a compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,~~ ~~including mixtures thereof in all ratios,~~

and

(b) an effective amount of a further medicament active ingredient.

33. (Currently Amended): A method according to claim 31, further comprising administering to said patient Use of compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 23 or of compounds of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases,~~
~~—— in combination with~~ at least one further medicament active ingredient.

34. (Currently Amended): An intermediate compound ~~Intermediate compounds of the formula I-1;~~



in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of which~~ in each case is monosubstituted or disubstituted by Hal,

R¹ is H, OH, OA, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or ethynyl,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

$\begin{array}{c} \text{E} \\ \text{C} \\ \text{W} \end{array}$ is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4-

or 3,5-diyl,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is COOH,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.

35. (Currently Amended): A compound ~~Compounds~~ according to Claim 34,
wherein said compound is selected from: the group consisting of

3-(4-chlorophenylcarbamoyl)oxazolidine-4-carboxylic acid,
 3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid,
 and isomers and salts thereof.

36. (Currently Amended): An intermediate compound ~~Intermediate compounds~~
 selected from: the group consisting of tert-butoxycarbonyl

(2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,

(2R,4S)- BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,

(2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,

(2R,4R)- BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,

alkyl (2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate

wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,

alkyl (2R,4S)- BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate,


alkyl (2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate

wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,

alkyl (2R,4R)- BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate, where alkyl has 1,
2, 3, 4, 5 or 6 carbon atoms,

and isomers and salts thereof.

37. (Currently Amended): An intermediate compound ~~Intermediate compounds~~ of
 the formula I-2



I-2

wherein in which


R^1 is H, =O, COOR^3 , OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

 is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, ~~each of which~~ in each case is monosubstituted or disubstituted by carbonyl oxygen,


A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.

38. (Currently Amended): A compound ~~Compounds~~ according to Claim 37 of ~~the~~ formula I-2a



I-2a


wherein in which

R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R³ is H or A,

 is pyrrolidine-1,2-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, ~~each of~~ which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.


39. (Currently Amended): A compound ~~Compounds~~ according to Claim 38, wherein said compound is selected from: the group consisting of

N-[4-(3-oxomorpholin-4-yl)phenyl]-(S)-pyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-pyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-hydroxypyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-4-hydroxypyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-4,4-dimethoxypyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-methoxypyrrolidine-2-carboxamide,
and isomers and salts thereof.

40. (Currently Amended): A medicament composition ~~Medicament~~ according to Claim 30, wherein said at least one compound is comprising 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or stereoisomers ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient is aspirin.

41. (Currently Amended): A method Use according to Claim 33, wherein
~~comprising~~ 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-
 hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate,
salt or stereoisomers ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures
 thereof in all ratios, and in combination with aspirin are administered to said patient.

42. (New): A compound according to claim 1, wherein



is pyrrolidine-1,2-diyl,

G is -NH-,

X is CONH,

Y is Ar-diyl,

Ar is phenyl which is substituted or unsubstituted; and

T is pyrrolidin-1-yl, is monosubstituted or disubstituted by carbonyl oxygen.